Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
This study is currently recruiting patients.
Sponsored by: | National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Chemotherapy drugs such as 17-N-allylamino-17-demethoxygeldanamycin work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 17-N-allylamino-17-demethoxygeldanamycin in treating patients who have von Hippel-Lindau disease and kidney cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
stage I renal cell cancer von Hippel-Lindau Syndrome |
Drug: 17-N-allylamino-17-demethoxygeldanamycin Procedure: chemotherapy |
Phase II |
MedlinePlus related topics: Cancer; Circulatory Disorders; Kidney Cancer; Neurologic Diseases
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel-Lindau Disease and Renal Tumors
OBJECTIVES: Primary
Secondary
OUTLINE: Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of unacceptable toxicity. Patients are evaluated for response after the third course. Patients with progressive or stable disease or whose renal tumor(s) is ≥ 3 cm undergo surgical resection of their tumor(s) off study. Patients with complete or partial response and whose renal tumor(s) is < 3 cm receive 3 additional courses of 17-AAG as above in the absence of unacceptable toxicity.
PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 2-3 years.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |